EP 127: Insights into precision medicine, fatty liver disease, and minimally invasive diagnostic tools with Dr. Mazen Noureddin

0:00 Intro
0:25 Mazen’s lifelong commitment to furthering the field of precision medicine in liver disease research, fueled by a personal connection of his grandmother developing MASH cirrhosis
2:30 Breakthroughs in the field of metabolic dysfunction-associated steatotic liver disease (MASLD) since the beginning of Mazen’s career
5:30 The potential impact of Resmetirom, a new drug that could treat MASLD and MASH cirrhosis
8:45 Significant takeaways from 40+ investigational clinical studies of novel treatments for MASLD/MASH
12:00 Alternatives to biopsies and potential tools for early, non-invasive diagnosis
19:00 Genetic determinants and risk factors for fatty liver disease
20:30 How Mazen uses genetic testing in the clinic for his patients
25:50 The impact of “miracle” weight loss drugs such as GLP-1s on patients with liver disease
29:30 The importance of early intervention to prevent late-stage cirrhosis
33:00 How to tailor treatment to consider environmental and epigenetic factors that impact genetic penetrance for liver disease
36:00 Potential links between metabolism and neurodegenerative conditions
39:00 Upcoming developments in MASLD and MASH research
41:00 Mazen’s relationship with his father, both as a dad and as a teacher